
Livanova (LIVN) Stock Forecast & Price Target
Livanova (LIVN) Analyst Ratings
Bulls say
LivaNova's financial performance has shown a positive trajectory, with an operating margin increase of 180 basis points year-over-year, driven by improved gross margins and strategic SG&A management. The company is forecasting mid-single-digit revenue growth of 6.7% for 2024, alongside strong expectations for its cardiopulmonary segment, anticipating organic growth of 7.0-8.0% in 2025 due to product launches and market share gains. Additionally, LivaNova is addressing capacity constraints in its oxygenator production, having improved capacity by 10% in 2024 and projecting further enhancements of 10-15% in 2025, which positions the company favorably for sustained growth.
Bears say
LivaNova has experienced a deceleration in revenue growth, particularly within its Neuromodulation segment, which rose only 1.0% to $137.6 million, significantly lower than the previous quarter's growth of 8.8%. Additionally, the company's Cardiopulmonary sales, while growing by 11.2% to $181.7 million, have also shown a decline from the 15.4% growth seen in the prior quarter, indicating underlying operational challenges. The company's bear case scenario forecasts a further slowdown in revenue growth to low-single digits, alongside anticipated operating margin contraction and earnings that may fall below consensus estimates, suggesting a challenging outlook for the firm.
This aggregate rating is based on analysts' research of Livanova and is not a guaranteed prediction by Public.com or investment advice.
Livanova (LIVN) Analyst Forecast & Price Prediction
Start investing in Livanova (LIVN)
Order type
Buy in
Order amount
Est. shares
0 shares